Case Studies

Challenge: A late pre-clinical biotech company engaged in the development of antibody drug conjugates (ADCs) targeting GPCRs for treatment of solid tumors asked Alacrita to conduct an internal due...

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...

Challenge A preclinical stage biotech company developing a novel formulation of insulin to treat diabetes mellitus was in discussions with prospective investors for a next round of funding. To...

Challenge An investment firm required independent valuations of five therapeutics within two of its portfolio companies, including four preclinical programs and a proprietary formulation of a...

Challenge A biotech company had developed preclinical data supporting the use of its lead drug candidate in enhancing male fertility. The product was being considered for both ex-vivo usage prior to...

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...

Challenge: Our client was developing oncolytic viruses for treating a rare form of brain cancer. Its lead product had been successfully evaluated in a Phase I dose-escalation study. Direct injection...

Challenge: Our client was developing oncolytic viruses for treating a rare form of brain cancer. Its lead product had been successfully evaluated in a Phase I dose-escalation study. Direct injection...

Challenge Alacrita supported the European arm of a major company creation investor as part of an ongoing workstream to evaluate the benefits of refocusing its investments into the tumour infiltrating...

Challenge: For a university with an early stage novel inhibitor of the JAK2/STAT5 pathway intended to treat hematologic malignancies, Alacrita was asked to validate a development plan to support...

Challenge An academic group was interested in developing and commercializing an AAV vector-delivered gene therapy for a cardiac indication through the formation of a NewCo. They required assistance...